Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
Baylor College of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University of Florida
Baylor College of Medicine
Emory University
Eli Lilly and Company
Seattle Children's Hospital
St. Jude Children's Research Hospital
Baylor College of Medicine
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
Nationwide Children's Hospital
Foghorn Therapeutics Inc.
Ipsen
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
Ipsen
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
University of Alabama at Birmingham
Y-mAbs Therapeutics
Emory University
City of Hope Medical Center
Dana-Farber Cancer Institute
Emory University
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)